About 813 results

ALLMedicine™ Oral Leukoplakia Center

Research & Reviews  294 results

Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers hav...
Journal of Oral Pathology & Medicine : Official Publicati... Sayal L, Hamadah O et. al.

Dec 3rd, 2022 - Cell-free DNA (cfDNA) and cell-free mitochondrial DNA (cf-mtDNA) have been postulated as potential diagnostic and prognostic biomarkers for different human malignancies. Early detection of head and neck malignancies is fundamental for optimal pati...

Elucidating the genetic landscape of oral leukoplakia to predict malignant transformation.
Clinical Cancer Research : an Official Journal of the Ame... Wils LJ, Poell JB et. al.

Dec 1st, 2022 - Oral leukoplakia is the most common oral potentially malignant disorder with an annual malignant transformation rate of 1-5%. Consequently, oral leukoplakia patients have a 30-50% lifetime risk to develop oral squamous cell carcinoma. Although ris...

Rapid diagnosis of a complex oral mucosal infection using metagenomic next-generation s...
The Journal of International Medical Research; Song Y, Song F et. al.

Nov 19th, 2022 - The most commonly used methods for pathogen detection and identification in oral mucosal infectious diseases are DNA or RNA quantitative polymerase chain reaction detection, bacterial or fungal cultures, and immunohistochemical analysis. These tra...

Significance of nuclear EGFR and ABCG2 expression in malignant transformation of oral p...
Head & Neck; Tarle M, Müller D et. al.

Nov 4th, 2022 - The purpose of this study was to investigate the expression of nuclear EGFR (nEGFR) and the stem cell marker ABCG2 in oral leukoplakia (OL) and oral erythroplakia (OE) and to assess their significance as prognostic biomarkers for malignant transfo...

Comparative Somatic Variant Analysis of a Rare Case with Concurrent Oral Leukoplakia an...
Cytogenetic and Genome Research; Anne A, Bindra S et. al.

Oct 24th, 2022 - Oral leukoplakia (OL) and oral submucosal fibrosis (OSMF) are precancerous conditions with common etiologies but with different risks for oral cancer (OC) progression. In rare cases, both conditions occur in the same patient and provide an opportu...

see more →

Clinicaltrials.gov  22 results

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To determine the histological response to extended release metformin hydrochloride (metformin) intervention in the target lesion. SECONDARY OBJECTIVES: I. Clinical response to metformin intervention in the target lesion. II. ...

Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia

Sep 22nd, 2022 - PRIMARY OBJECTIVE: I. Evaluate the feasibility of intralesional 5-fluorouracil (5-FU) injection for the treatment of oral leukoplakia SECONDARY OBJECTIVE: I. Evaluate the safety profile and side effects of the study drug. OUTLINE: Participants dia...

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Apr 29th, 2022 - Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum of telomere biology disorders, which i...

Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD)

Mar 25th, 2022 - In Sweden, about 1,200 cases of cancer of the oral cavity, lips and throat are diagnosed each year. This is significantly higher than the global age-standardized incidence of 6.1 per 100,000 inhabitants, including all ages and genders. Oral cancer...

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Feb 11th, 2022 - PRIMARY OBJECTIVES: I. Determine whether pioglitazone (pioglitazone hydrochloride) reverses leukoplakia in patients with hyperplastic or dysplastic oral cavity or oropharyngeal leukoplakia. SECONDARY OBJECTIVES: I. Determine the safety and tolerab...

see more →

News  8 results

Could Nivolumab Prevent Oral Cancer in High-Risk Patients?

Sep 12th, 2022 - The immune checkpoint inhibitor nivolumab (Opdivo) appears to prevent the transformation of oral proliferative leukoplakia (PL), a high-risk precancerous disease, into oral cancer, suggest the results from a phase 2 study. “We think that immunothe...

Dr Waun Ki Hong Reflects on Career Milestones in ASCO 2018 Interview

Dec 20th, 2020 - Waun Ki Hong, MD Pivotal clinical trials in oncology that laid the groundwork for organ preservation, chemoprevention, and precision medicine can be traced back to pioneering medical oncologist Waun Ki Hong, MD. Hong, who was the former head of ...

Clinical Trials in Progress

Dec 5th, 2020 - The Trials in Progress section is intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the oncology community. Each month, OBTN will present summaries of ongoing research in a broad range of cancer typ...

Tylosis in a Patient With Howel-Evans Syndrome: Management With Acitretin
Sabra M. Abner, MD, Audra Isaac, MD et. al.

Nov 4th, 2020 - To the Editor: Tylosis with esophageal cancer was first described by Howel-Evans et al1 in 1958 in a family from Liverpool, England. The disease is inherited in an autosomal-dominant fashion with a mutation in the tylosis with esophageal cancer ge.

Management Strategies for Oral Potentially Malignant Disorders

Mar 16th, 2018 - Oral Potentially Malignant Disorders Oral potentially malignant disorders (OPMDs) include oral leukoplakia (OL), oral erythroplakia, oral submucous fibrosis, oral lichen planus, proliferative verrucous leukoplakia, and actinic keratosis. Once an O...

see more →

Patient Education  1 results see all →